Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. TScan Therapeutics, Inc.
  6. News
  7. Summary
    TCRX   US89854M1018

TSCAN THERAPEUTICS, INC.

(TCRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TScan Therapeutics : Cowen Initiates Coverage on TScan Therapeutics With Outperform Rating

08/13/2021 | 06:18am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2021
All news about TSCAN THERAPEUTICS, INC.
05/19TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell T..
GL
05/19TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell T..
AQ
05/17TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
GL
05/17TScan Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
AQ
05/12TSCAN THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a..
AQ
05/12TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strateg..
GL
05/12TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strateg..
AQ
05/10HC Wainwright Lowers TScan Therapeutics Price Target to $15 From $21, Maintains Buy Rat..
MT
05/09TScan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,..
CI
05/09TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipate..
GL
More news
Analyst Recommendations on TSCAN THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 12,8 M - -
Net income 2022 -71,1 M - -
Net cash 2022 77,4 M - -
P/E ratio 2022 -0,94x
Yield 2022 -
Capitalization 69,0 M 69,0 M -
EV / Sales 2022 -0,66x
EV / Sales 2023 -1,56x
Nbr of Employees 105
Free-Float 56,8%
Chart TSCAN THERAPEUTICS, INC.
Duration : Period :
TScan Therapeutics, Inc. Technical Analysis Chart | TCRX | US89854M1018 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 2,88 $
Average target price 14,00 $
Spread / Average Target 386%
EPS Revisions
Managers and Directors
David P. Southwell President, Chief Executive Officer & Director
Brian Michael Silver Chief Financial Officer & Treasurer
Timothy Joseph Barberich Chairman
Gavin MacBeath Chief Scientific Officer
Jim Murray Vice President-Clinical
Sector and Competitors
1st jan.Capi. (M$)
TSCAN THERAPEUTICS, INC.-36.00%69
MODERNA, INC.-48.00%52 528
LONZA GROUP AG-27.13%42 896
IQVIA HOLDINGS INC.-28.41%38 232
SEAGEN INC.-13.67%24 569
ICON PUBLIC LIMITED COMPANY-30.17%17 581